Some people with slow hepatitis B think that if they have hepatitis B, they can just take medication and get injections, and there is no need to do tests and go by their feelings. In fact, this is not right. Before interferon antiviral therapy should be checked: 1, biochemical indicators, including ALT, AST, bilirubin, albumin and kidney function; 2, routine blood, thyroid function, blood sugar and urine routine; 3, virological markers, including HBsAg, HBeAg, anti-HBe and HBV DNA levels; 4, for middle-aged patients and above, electrocardiography and blood pressure should be measured; 5, detection of autoantibodies 6. Women of childbearing age should also be tested for human chorionic gonadotropin (HCG) to exclude pregnancy. During the course of treatment, the following tests should be performed: 1) routine blood tests should be performed every 1 to 2 weeks in the first month after the start of treatment, and then once a month until the end of treatment; 2) biochemical indicators, including ALT and AST, should be performed once a month for 3 consecutive times after the start of treatment, and then once every 3 months as the disease improves; 3) virological markers, HBsAg, HBeAg, anti-HBeAg and anti-HBeA, should be performed once every 3 months after the start of treatment. HBeAg, anti-HBe and HBV DNA every 3 months after the start of treatment; 4. Other, thyroid function, blood glucose and urinary routine should be tested every 3 months; 5. Before the application of nucleoside (acid) analogues treatment: 1, biochemical indicators including ALT, AST, bilirubin, albumin, etc.; 2, virological markers including baseline status or level of HBeAg, anti-HBe and HBV DNA; 3, according to the needs of the disease, testing routine blood, phosphocreatine kinase and serum creatinine, etc.. In addition, liver aspiration examination is feasible before and after treatment in units with conditions. The relevant indicators should be monitored and followed up regularly during the treatment to evaluate the efficacy and improve compliance: 1.biochemical indicators once a month for 3 times after the start of treatment, and once every 3 months afterwards as the condition improves; 2.virological markers HBsAg, HBeAg, anti-HBe and HBV DNA should be tested once every 3 months after the start of treatment; 3.according to the condition, routine blood tests, serum phosphocreatine kinase and creatinine should be performed. Phosphocreatine kinase and creatinine, etc. These indicators will play a guiding role in predicting and judging the efficacy of treatment, detecting adverse drug reactions, preventing drug resistance and reducing relapse. It is not something that is optional. Patients with hepatitis B are advised not to emphasize treatment over screening.